Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.
Naomi B. Haas, MD, medical oncologist, director of the Prostate and Kidney cancer Program and professor of Medicine at the Hospital of the University of Pennsylvania, discusses the potential benefits of lenvatinib (Lenvima) for the treatment of renal cell carcinoma (RCC).
According to Haas, there are phase 2 studies ongoing to investigate the benefit of lenvatinib in patients with RCC. One potential benefit is that lenvatinib may augment its activity with immune checkpoint inhibitors. Additionally, some data suggests that it helps to stimulate regulatory T cells and prevent T-cell exhaustion. Haas says that these are the 2 reasons why immune checkpoint inhibitors sometimes do not work in this patient population.
0:08 | There are certainly phase 2 initiatives that are being done to understand the benefit in patients. Lenvatinib is an interesting drug because it probably also has some immunologic aspects that can augment its activity with immune checkpoint inhibitors. So, there's some data to suggest that it might help stimulate regulatory T cells and it might be a way to prevent T-cell exhaustion, which are 2 reasons that immune checkpoint inhibitors sometimes don't work in patients. So, I think it's a very useful approach and I feel encouraged about that.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More